|Bid||21.13 x 800|
|Ask||23.71 x 800|
|Day's Range||22.89 - 23.73|
|52 Week Range||21.25 - 33.80|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of September 30. In this […]
Trailing twelve-month data shows us that Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) earnings loss has accumulated to...
On a per-share basis, the South San Francisco, California-based company said it had a loss of 32 cents. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks ...
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Allogene Therapeutics, Inc. (NASDAQ:ALLO) with a market-capitalization of US$3.2b, rarely draw their attention. However, generally ignored mid-capsRead More...